CTIS.eu › Cities › Poland › Radom
Radom
Poland
22 total trials
7 recruiting
2025-522362-78-00
6
severely active ulcerative colitis (US) and CD (Crohn’s disease)
2025-523461-17-01
5
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
2024-512360-55-00
4
2025-06-30
Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
2025-523123-22-00
5
2026-05-07
Chronic Kidney Disease
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
2024-517972-39-00
5
2025-08-19
Autoimmune haemolytic anaemia
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
2024-517880-22-00
5
2023-01-04
Protein-energy wasting in nephrotic syndrome
2024-510908-37-00
5
2024-08-28
KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (
2023-506917-23-00
4
2024-04-19
patients with mild to moderate left-sided ulcerative colitis
2023-504124-26-00
5
2024-04-04
Chronic Kidney Disease and High Proteinuria
2022-501744-15-00
5
2023-01-23
Obesity, Overweight
2022-502122-41-00
5
2021-05-11
Clear cell renal cancer
2023-505852-23-00
5
2020-11-12
High risk recurrent prostate cancer previously treated with radical pr
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C
2023-503298-39-00
5
2024-06-13
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
2023-507705-34-00
5
2025-08-29
Moderate to Severe Active Ulcerative Colitis
2023-507206-13-00
5
2024-03-14
Type 2 Diabetes
2022-502234-70-00
5
2023-07-14
Chronic Obstructive Pulmonary Disease (COPD)
2023-505457-40-00
5
2022-02-02
Previously Untreated Advanced Gastric or Gastroesophageal Junction
Can
2023-507024-24-00
5
2020-05-05
Metastatic hormone sensitive prostate cancer
Showing 1–22 of 22 trials